The US companies Genentech and Tanox Biosystems have settled lawsuits filed by each company against the other. Tanox had filed a lawsuit against Genentech, relating to development of anti-1gE monoclonal antibodies, and Genentech had filed a patent infringement lawsuit against Tanox and Ciba-Geigy. These two companies were jointly developing an anti-1gE antibody product for use in the treatment of allergies and allergic asthma. Genentech has been developing its product independently.
All three firms have reached an agreement in principle under which they will combine their existing anti-1gE antibody programs into a cooperative development effort. A definitive agreement will be concluded within the next six months.
Following the combining of programs, the most promising anti-1gE antibody product will be selected for further development and commercialization. Ciba will share marketing opportunities with Genentech in the USA and Europe. Hoffmann-La Roche, which has certain existing agreements with Genentech, also will have an option to participate in marketing the anti-1gE antibody product in Europe and Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze